JPH203, an SLC7A5 (LAT1) inhibitor, which is also highly expressed in HNSCC, has completed phase II clinical trials in advanced biliary tract cancer and has shown promise in the prevention of biliary tract cancer [67]. Here, SLC7A5 is linked to biliary tract neoplasm.